GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Kedudukan dalam Saham
#3666
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Harga Saham
$27.17
Modal Pasaran
$4.60B
Perubahan (1 hari)
-1.33%
Perubahan (1 tahun)
-13.30%
Negara
IN
Perdagangan GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Hasil untuk GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Hasil pada Jun 2026 TTM: $436.46M
Menurut laporan kewangan terkini daripada GlaxoSmithKline Pharmaceuticals Limited, hasil semasa syarikat (TTM) ialah $436.46M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $414.20M peningkatan berbanding hasil pada tahun 2023 iaitu $395.68M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi GlaxoSmithKline Pharmaceuticals Limited dari 2004 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $436.46M | -0.43% |
| 2025 | $438.37M | 5.84% |
| 2024 | $414.20M | 4.68% |
| 2023 | $395.68M | -8.37% |
| 2022 | $431.83M | 8.05% |
| 2021 | $399.65M | -6.62% |
| 2020 | $428.01M | -4.99% |
| 2019 | $450.48M | 2.15% |
| 2018 | $441.02M | -1.67% |
| 2017 | $448.50M | 4.70% |
| 2016 | $428.36M | 1.31% |
| 2015 | $422.83M | -0.90% |
| 2013 | $426.68M | -11.70% |
| 2012 | $483.21M | 7.85% |
| 2011 | $448.05M | -6.91% |
| 2010 | $481.30M | 17.28% |
| 2009 | $410.39M | 17.56% |
| 2008 | $349.09M | -14.58% |
| 2007 | $408.65M | 14.51% |
| 2006 | $356.86M | 5.90% |
| 2005 | $336.97M | 3.85% |
| 2004 | $324.46M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $79.67B | 18,152.62% |
US
|
|
| $99.34B | 22,659.12% |
US
|
|
| $64.39B | 14,651.79% |
US
|
|
| $66.40B | 15,113.23% |
US
|
|
| $77.52B | 17,660.65% |
CH
|
